Congenital Hyperinsulinism International (CHI) is offering a pilot research grant to generate new insights into hyperinsulinism hyperammonemia (HIHA, also called GDH-HI), with the goal of adding to a body of knowledge leading to new and better treatments, and a cure, one day.
In May 2019, CHI will award the one-year grant. Funding of $70,000 will be available for an innovative, preclinical, or clinical study that has the potential to lead to: (1) a better HIHA treatment; (2) a cure for HIHA; or (3) a quality of life improvement for those affected by HIHA.
HIHA is the second most common form of HI. It is caused by a defective GDH (glutamate dehydrogenase) gene. GDH is an enzyme which plays an important role in amino acid metabolism. People with HIHA secrete too much insulin which causes hypoglycemia, especially after a protein rich intake. Those with HIHA also have high ammonia levels in their blood, and often have epilepsy and other neurological issues that are thought to stem from the change in the GDH gene. The only currently available treatment for HIHA helps in the management of hypoglycemia but leaves the high ammonia levels untreated.
A Request for Applications (RFA) is available below. Applications are due on April 8, 2019 by 24:00 EDT. Applications will be reviewed by a committee of experts in the field, and the award will be announced on May 20, 2019. This funding opportunity is open to independent researchers, tenure-track faculty, non-tenure-track faculty or staff, or an equivalent level at a research institution or at a biotechnology/pharmaceutical company.
Click here for the HIHA Request for Application (RFA), which includes information on the following:
- HIHA Pilot Grant Background
- Application Instructions
- Format for documents
- Content to be emailed
- Grant review procedure
- Fund disbursement